Bluejay Diagnostics, Inc.
BJDX Healthcare Medical Devices
Bluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00. In the quarter to June 2026, EPS grew 80.1% and free cash flow grew 20.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow BJDX
Bluejay Diagnostics, Inc. (BJDX) P/E ratio
As of 16 October 2026, Bluejay Diagnostics, Inc. (BJDX) trades at a P/E ratio of 0.9×. Over the past ten years it has ranged from 0.0× (June 2026) to 1.8× (July 2026); the current reading is higher than 94% of that period. That is below the Medical Devices industry median of 23.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2022 | 0.0× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NXL Nexalin Technology, Inc. compare | n/m |
| INBS Intelligent Bio Solutions Inc. compare | n/m |
| TRIB Trinity Biotech PLC compare | n/m |
| VVOS Vivos Therapeutics, Inc. compare | n/m |
| ICCM IceCure Medical Ltd. compare | n/m |
| ADGM Adagio Medical Holdings, Inc. compare | n/m |
| BIOLQ Biolase, Inc. compare | n/m |
| IVF INVO Fertility, Inc compare | 0.0× |
| BJDX Bluejay Diagnostics, Inc. | 0.9× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)